Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Assertio Therapeutics ( (ASRT) ) has provided an update.
On April 29, 2026, Assertio announced that it had mutually agreed with Garda Therapeutics to extend to May 4, 2026 the deadline to commence Garda’s previously announced tender offer to acquire all outstanding Assertio shares. The extension follows the April 8, 2026 definitive merger agreement under which Garda plans to acquire Assertio for $18.00 per share in cash, valuing the deal at about $125.1 million plus a contingent value right.
The merger agreement includes a 20-day window-shop period that allows Assertio to engage with other potential bidders that might deliver superior value to shareholders. If the board terminates the Garda deal in favor of a higher offer during this period, a reduced breakup fee would apply, preserving flexibility for investors while maintaining a structured path toward a potential sale of the company.
The most recent analyst rating on (ASRT) stock is a Hold with a $18.05 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.
Spark’s Take on ASRT Stock
According to Spark, TipRanks’ AI Analyst, ASRT is a Neutral.
The score is held back primarily by weak financial performance—declining revenue, ongoing losses, and a 2025 shift to negative operating/free cash flow. Technicals are moderately supportive with the stock above key moving averages and positive MACD. The earnings outlook is constructive on FY2026 guidance and Rolvedon-driven profitability expansion, while the acquisition event adds meaningful deal-value support that partially offsets the fundamental and cash-flow risk.
To see Spark’s full report on ASRT stock, click here.
More about Assertio Therapeutics
Assertio Holdings, Inc. is a pharmaceutical company with commercial capabilities focused on marketing differentiated therapies, primarily in the oncology market. The company’s portfolio is positioned to address patients’ needs in cancer care, where it competes in a specialized segment of the broader biopharmaceutical industry.
Average Trading Volume: 140,886
Technical Sentiment Signal: Hold
Current Market Cap: $116.3M
See more data about ASRT stock on TipRanks’ Stock Analysis page.